Drug Trial Radar · NCT07511556
First-in-human Study of UX016 in GNEM
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to assess the safety and dose of UX016 and its impact on muscle strength in adults with GNE Myopathy (GNEM).
Conditions
- GNE Myopathy
Interventions
UX016Drug
Tablets for oral use
PlaceboOther
Tablets for oral use. Tablets will match the UX016 tablets, but contain no active ingredients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 96 (Double Blind and Extension Periods)
- Upper Extremity Composite (UEC) Score Change From BaselineTime frame: Baseline, 48 Weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of California, Irvine
Orange, California · Recruiting
Rare Disease Research
Iselin, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.